Latest Vitura Health (ASX:VIT) News

Speculative resources names drove the biggest moves this week, with Patriot Resources, Brazilian Critical Minerals and Rent.com.au leading the gainers. At the other end, Qoria, SQX Resources and 4DMedical fell hard as capital raisings, weak follow-through and post-gap selling hit sentiment.

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.

Vitura Health’s telehealth arm, Doctors on Demand, has hit a major milestone of over 1 million consultations since FY2024, while delivering sustained EBITDA profitability and a 54% revenue increase over two years to $21.6 million in FY2026 Q1-Q3.

Big moves came from point-of-care testing and a sharp sell-off in two names despite upbeat news. Meanwhile, several smaller caps pushed trials and regulatory files forward, giving investors clear dates to watch.

Vitura Health has appointed Justin James as its new CEO, bringing a wealth of healthcare leadership and a proven track record in specialty therapies to accelerate the company’s transformation.

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.

Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

Vitura Health Limited reported an 8.3% rise in half-year revenues to $67.87 million, driven by medicinal cannabis sales and telehealth services, yet posted a consolidated loss of $986,341 due to margin pressures and increased costs. Leadership changes and strategic investments mark a pivotal phase for the digital health and medicinal cannabis player.

Vitura Health has announced the departure of CEO Geoff Cockerill, appointing Chief Revenue Officer Ryan Tattle as interim leader while accelerating the search for a new CEO. Incoming CFO Andrew Cook will join ahead of schedule, signalling a renewed focus on operational and financial discipline.

Vitura Health Limited has updated its dividend distribution details, confirming a fully franked ordinary dividend and issuing nearly 487,000 new shares under its Dividend Reinvestment Plan.